BURLINGAME, Calif.–(BUSINESS WIRE)–Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) (“Entasis”) at a price of $2.20 per share, net to the seller in cash, without interest and less required withholding taxes, expired at … [Read more…]
WESTLAKE, Ohio–(BUSINESS WIRE)–Nordson Corporation (Nasdaq: NDSN) today announced a strategic business segment realignment that reinforces the Company’s focus on its long-term profitable growth strategy. The Company will reorganize into three financial reporting segments effective August 1, 2022: Industrial Precision Solutions (IPS) led by Jeffrey A. Pembroke, Executive Vice President; Medical and Fluid Solutions (MFS) led … [Read more…]
RICHMOND, Va.–(BUSINESS WIRE)–Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system, today announces that its therapeutic program Adimune™, has successfully completed a toxicology study that indicates the safety profile of ADI™-100, the Company’s immunotherapeutic technology drug that addresses rejection of … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “IVD Raw Materials Market – Global Outlook & Forecast 2022-2027” report has been added to ResearchAndMarkets.com’s offering. With the rise in chronic conditions and patient populations, the demand for diagnostics and laboratory tests increases. The growing demand for antigen and antibody-based tests that increased during COVID-19 led to its major market share. The … [Read more…]
Analyses of the first three patients at 6 months post-treatment showed increases in white matter and myelin and improvements on validated functional scales To date, 5 patients have been treated in the ongoing Phase 1/2 First-in-Human clinical trial with favorable safety and tolerability Encouraging early data support further development of rAAV-Olig001-ASPA as a potential therapeutic … [Read more…]
BRIDGEWATER, N.J.–(BUSINESS WIRE)–Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2022 financial results on Friday August 5, 2022, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on August 5, 2022. The financial results … [Read more…]
BOTHELL, Wash.–(BUSINESS WIRE)–Seagen Inc. (Nasdaq: SGEN) today announced that it will report its second quarter 2022 financial results on Thursday, July 28, 2022 after the close of U.S. financial markets. Following the announcement, Company management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business … [Read more…]
— Approval based on MIRROR randomized controlled trial, which showed significant improvement and sustained patient response to KRYSTEXXA with methotrexate compared to KRYSTEXXA alone — — Trial data showed a greater than 30 percentage-point increase in efficacy, and a significant reduction in infusion reactions from 31% to 4% — — Priority review was granted for … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “U.S. Primary Care Physicians Market Size, Share & Trends Analysis Report by Type (General Practice, Family Physician & Geriatrics, General Internal Medicine), and Segment Forecasts, 2022-2030” report has been added to ResearchAndMarkets.com’s offering. The U.S. primary care physicians market size is expected to reach USD 341.9 billion by 2030. The market is projected … [Read more…]
CLEVELAND–(BUSINESS WIRE)–$ATHX–Athersys, Inc. (Nasdaq: ATHX) today announced that its equity purchase agreement with Aspire Capital Fund LLC (Aspire Capital) has been terminated. The Company continues to evaluate alternative financing options to support continuing operations. After several discussions with Aspire Capital, Athersys received notice on July 6, 2022 of termination of the equity purchase agreement, effective … [Read more…]
